about
Management of hepatocellular carcinoma in the elderlyTransarterial radioembolization for hepatocellular carcinoma: An update and perspectivesAssessment of clinical and radiological response to sorafenib in hepatocellular carcinoma patientsDevelopment and Validation of a New Prognostic System for Patients with Hepatocellular CarcinomaActive Targeting of Sorafenib: Preparation, Characterization, and In Vitro Testing of Drug-Loaded Magnetic Solid Lipid Nanoparticles.Endotics system vs colonoscopy for the detection of polyps.Hepatitis C virus core protein modulates pRb2/p130 expression in human hepatocellular carcinoma cell lines through promoter methylationBoceprevir or telaprevir in hepatitis C virus chronic infection: The Italian real life experience.Clinical impact of selective transarterial chemoembolization on hepatocellular carcinoma: a cohort studyDissecting signaling pathways in hepatocellular carcinoma: new perspectives in medical therapy.Transarterial chemoembolization and sorafenib in hepatocellular carcinoma.Adacolumn leucocytapheresis for ulcerative colitis: clinical and endoscopic features of responders and unresponders.Assessment of radiologic response to targeted therapies in patients with hepatocellular carcinoma.Enteral nutrition for maintaining remission in patients with quiescent Crohn's disease: current status and future perspectives.Trans-Arterial Radioembolization for Hepatocellular Carcinoma.Recurrence of hepatocellular carcinoma after liver transplantation: an update.Curative therapies for hepatocellular carcinoma: an update and perspectives.Report from European Association for the Study of the Liver: HCC Summit, Geneva, Switzerland, 2-5 February 2017.Hepatocellular carcinoma recurrence in patients with curative resection or ablation: impact of HCV eradication does not depend on the use of interferon.Years of life that could be saved from prevention of hepatocellular carcinoma.Management and prognosis of hepatocellular carcinoma in the elderly: Results of an in-field multicenter cohort study.Hepatic decompensation is the major driver of death in HCV-infected cirrhotic patients with successfully treated early hepatocellular carcinoma.Efficacy and safety of sofosbuvir/simeprevir plus flat dose ribavirin in genotype 1 elderly cirrhotic patients: A real-life study.Antiapoptotic regulation by hepatitis C virus core protein through up-regulation of inhibitor of caspase-activated DNase.The evolutionary scenario of hepatocellular carcinoma in Italy: an update.Comparison between alcohol- and hepatitis C virus-related hepatocellular carcinoma: clinical presentation, treatment and outcome.Utility-based criteria for selecting patients with hepatocellular carcinoma for liver transplantation: A multicenter cohort study using the alpha-fetoprotein model as a survival predictor.Survival benefit of liver resection for patients with hepatocellular carcinoma across different Barcelona Clinic Liver Cancer stages: a multicentre study.Correlation between LDH levels and response to sorafenib in HCC patients: an analysis of the ITA.LI.CA database.Determinants of alpha-fetoprotein levels in patients with hepatocellular carcinoma: implications for its clinical use.The calm before the storm: a report from the International Liver Cancer Association Congress 2015 - part 2.Dietary supplementation in cancer patients: a personal view of current status and future perspectives.Assessment of response to sorafenib in advanced hepatocellular carcinoma using perfusion computed tomography: results of a pilot study.The calm before the storm: a report from the International Liver Cancer Association Congress 2015--part 1.Emergence of hepatitis B virus quasispecies with lower susceptibility to nucleos(t)ide analogues during lamivudine treatment.Treatment options for children and adolescents with inflammatory bowel disease: is granulomonocytapheresis an effective alternative to drug therapy?Bismuth-based quadruple therapy following H. pylori eradication failures: a multicenter study in clinical practice.Curative therapies are superior to standard of care (transarterial chemoembolization) for intermediate stage hepatocellular carcinoma.Transarterial chemoembolization and sorafenib in patients with intermediate-stage hepatocellular carcinoma: time to enter routine clinical practice?European Association for the Study of the Liver Hepatocellular Carcinoma summit 2014: old questions, new (or few) answers?
P50
Q26827161-3735D440-B1A4-4642-B30B-04373B49BA4EQ28081783-D0675F54-86A6-48D0-A37B-A77B8BE76DB1Q28086977-EB575E4B-632D-4E36-B352-3B1EFD9F97B1Q28551586-63C373BA-3887-451A-BBBC-5F888F6BFB5DQ30964683-35E1C910-CCC1-454C-84AD-FD3BCBC4753FQ34333152-BECE89E9-ABEE-499F-98B2-235F61223C00Q36294409-9E26D910-CDB3-407F-9B5D-2D13CEEF15E8Q37157057-57E3D5F1-924F-4FF0-AE41-F6134954B6D2Q37161614-4C264725-AB7C-457A-83E1-6C55117F24CEQ38184582-0780D047-0D4C-405E-8D14-CA4EB130680DQ38213650-8382F423-962E-4DEE-B0E6-27A8EA85CDA2Q38243723-D2D0341D-600F-4B60-B3B7-3E0D5E9DDB9EQ38268169-70378A07-CBF4-4EC5-85DD-9AB27D4F353DQ38566426-BA0732E8-E306-49AD-8705-2462E60E918FQ38591621-D68613BA-EDE3-4B41-8FBF-FC4F477ED7CCQ38594469-3539C47B-4E23-41A0-855A-BEED57846D2AQ38640531-7E41BC8D-B0A3-4CBE-9079-43D868BD3D3FQ38673823-F87CBA70-68A9-45C1-8E2D-9BF3F58B9EB1Q39240225-37796B68-5E71-4549-AFC4-ECC1E9D305F2Q40007128-490E8F8A-8FD2-46DA-BB7D-F40EB551BEDEQ40327172-E7C2E266-B4B5-4A5B-8C9C-A80AED009F4BQ40335094-639A765F-5994-482B-8EE7-8E2E79585033Q40484806-A645AB3E-A8A9-4F38-96E8-B1AA2930455FQ40607475-B4D963C5-6025-4BA5-9267-1B5E6B2E256DQ40646684-88F90598-A384-46CA-B662-B634AE30D3A9Q41054698-17B95DEE-FE56-458A-84AB-FAE3B315BCA4Q41578261-21F8FF2B-E51D-4C3A-8EA9-8D2F903644BCQ41633380-1BDBA713-2DB2-45BC-8FCD-3248D3B8C360Q41754691-4DD576CB-5C8A-45EB-925F-F1E0BC466A95Q42225289-F09CCF6F-DD8A-47F2-99BE-0C6A74E7204AQ43661853-B666D8B9-1E25-4B14-B400-56E642AD8682Q44019395-1B8D326D-0CCA-428D-B6D4-D0665CC97572Q44609197-21461E0C-E796-491E-9971-3BCF7904E607Q44634188-111052C8-DADD-461F-9948-E7E9CDE58F45Q45402989-6352812D-C358-452A-ACD6-588AFD25B3D8Q47694487-324EBEB5-9DDF-46B6-8A63-CE2BA66E8E4CQ47770110-3E07E936-7BDA-45D6-8C5D-99BD5B10CEB1Q48092299-122C5900-1DFA-4209-9C6D-A603CD7F00ECQ48411584-FA310C47-BD3D-4D54-814B-7CC049683EA4Q48760305-BF0C64E9-EFCE-4252-98E5-4F649389A5DE
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Rodolfo Sacco
@ast
Rodolfo Sacco
@en
Rodolfo Sacco
@es
Rodolfo Sacco
@nl
Rodolfo Sacco
@sl
type
label
Rodolfo Sacco
@ast
Rodolfo Sacco
@en
Rodolfo Sacco
@es
Rodolfo Sacco
@nl
Rodolfo Sacco
@sl
prefLabel
Rodolfo Sacco
@ast
Rodolfo Sacco
@en
Rodolfo Sacco
@es
Rodolfo Sacco
@nl
Rodolfo Sacco
@sl
P106
P1153
7101699492
P21
P31
P496
0000-0002-9887-7315
P569
2000-01-01T00:00:00Z